US Patent Expanded by Further Claims Allowance

7/8/2016: I was granted additional claims on my previous patent:

8,263,069 Composition including anthocyanins and anthocyanidins for prevention and or treatment of articular cartilage associated conditions. September 11, 2012.

The claims now include the direct intra articular injection of the phytochemical anthocyanin.  I now will submit an application for the phase I metabolite; protocatechuic acid for intra articular injection.

The claims allowed were:

 A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in an arthritic joint of a subject, comprising administering into the arthritic joint of the subject, an intra-articular injection, a composition that is a solution consisting of an anthocyanin, glucose and a pharmaceutically acceptable carrier,

wherein said glucose is a 5% solution, and

wherein the anthocyanin is cyanidin-3-glucoside and said cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint

  1. The method according to claim 1, wherein the composition increases gene expression of IGF-l in the arthritic joint.
  1. The method according to claim 1, wherein inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in the arthritic joint of a subject is associated with a chondroprotective effect in the joint of a subject.
  1. The method according to claim 1, wherein inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside release in the arthritic joint of a subject is associated with a chondronutritive effect in the joint of a subject.
  1. The method of claim 1 wherein the joint is a synovial joint.
  1. A method for treating damaged cartilage in an arthritic joint in a subject, comprising the intra-articular injection of a composition consisting of an anthocyanin, glucose and a pharmaceutically acceptable carrier into the arthritic joint of a subject,

wherein said glucose is a 5% solution, and

wherein the anthocyanin is cyanidin-3-glucoside said cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint

  1. The method according to claim 6, wherein the composition stimulates the production of insulin-like growth factor -1 (IGF-1) in the joint to regenerate the damaged cartilage.
  1. The method of claim 6 wherein the joint is a synovial joint.

Comments

comments